ArticleInternational journal of ophthalmology2025
Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo describe the influence of adding topical nepafenac to both; oral eplerenone and intravitreal aflibercept on serous foveal detachment in eyes with central serous chorioretinopathy (CSCR).
methodsThis retrospective cohort study included 31 eyes with non-resolving and recurrent CSCR that have been treated between 2015 and 2022 at Kasr Alainy Hospital. They were subdivided into Group A, which had been treated with a combination of systemic eplerenone, intravitreal aflibercept and topical nepafenac, and Group B, which had been treated with a combination of systemic eplerenone and intravitreal aflibercept (without topical nepafenac). Our outcome measures included changes in the best corrected visual acuity (BCVA), central subfield macular thickness (CMT) and serous detachment height (SDH) at baseline and at 2mo after treatment.
resultsGroup A included 16 eyes. BCVA improved significantly from a logMAR of 0.62±0.44 to 0.42±0.47 (
conclusionUsing topical nepafenac in combination with both systemic eplerenone, and intravitreal aflibercept may provide better results in the treatment of CSCR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.